Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283751 · ClinicalTrials.gov registry record · Phase 3
Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 583
- Enrollment target
NCT00283751 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 583 participants.
The verdict
NCT00283751, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 583 participants
- Enrollment target
Study Summary
This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to test if Insulin Detemir as add-on to current Oral Antidiabetic Drug treatment is at least as effective as Insulin Glargine as add-on to current Oral Antidiabetic Drug treatment in reducing HbA1c in patients with Type 2 Diabetes.
Interventions
- DRUG insulin glargine
- DRUG insulin detemir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 583 participants |
| Start Date | 2003-03 |
| Est. Completion | 2004-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00283751
The ClinicalTrials.gov registry entry for NCT00283751 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 583 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which insulin glargine is the first listed.
NCT00283751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00283751 about?
NCT00283751 is a clinical study titled "Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes". This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to test if Insulin Detemir as add-on to current Oral Antidiabetic Drug treatment is at least as effective as Insulin Glargine as add-on to current Oral Antidiabetic Drug treatment in reducing HbA1c in p...
What is the current status of trial NCT00283751?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 583 participants. The study started on 2003-03. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00283751?
The interventions under investigation include: insulin glargine (DRUG), insulin detemir (DRUG).
Who is sponsoring clinical trial NCT00283751?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.